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Abstract
Background: The	majority	of	epidemiological	studies	concerning	possible	adverse	ef‐
fects	of	paracetamol	(acetaminophen)	in	pregnancy	have	been	focussed	on	childhood	
asthma.	Initial	results	of	a	robust	association	have	been	confirmed	in	several	studies.	
Recently,	a	few	cohort	studies	have	 looked	at	particular	neurocognitive	outcomes,	
and	several	have	implicated	hyperactivity.
Objectives: In	order	 to	confirm	these	 findings,	 further	 information	and	results	are	
required.	Here,	we	assess	whether	paracetamol	 intake	between	18	and	32	weeks	
gestation	is	associated	with	childhood	behavioural	and	cognitive	outcomes	using	a	
large	population.
Methods: Data	 collected	by	 the	Avon	Longitudinal	 Study	of	Parents	 and	Children	
(ALSPAC)	at	32	weeks	gestation	and	referring	to	the	period	from	18	to	32	weeks,	
identified	43.9%	of	women	having	taken	paracetamol.	We	used	an	exposome	analy‐
sis	first	to	determine	the	background	factors	associated	with	pregnant	women	taking	
the	drug,	and	then	allowed	for	those	factors	to	assess	associations	with	child	out‐
comes	(measured	using	regression	analyses).
Results: We	identified	15	variables	independently	associated	with	taking	paraceta‐
mol	in	this	time	period,	which	were	used	as	potential	confounders.	Of	the	135	neu‐
rocognitive	variables	considered,	adjusting	for	the	likelihood	of	false	discovery,	we	
identified	 56	 outcomes	 for	 adjusted	 analyses.	 Adjustment	 identified	 12	 showing	
independent	 associations	with	 paracetamol	 use	 at	P	 <	 .05,	 four	 of	which	were	 at	
P	<	.0001	(all	related	to	child	behaviours	reported	by	the	mother	at	42	and	47	months;	
eg	 conduct	 problems:	 adjusted	mean	 score	 +	 0.22	 (95%	 confidence	 interval	 0.10,	
0.33)).	 There	were	 few	associations	with	 behavioural	 or	 neurocognitive	 outcomes	
after	age	7‐8	years,	whether	reported	by	the	mother	or	the	teacher.
Conclusions: If	paracetamol	use	in	mid‐to‐late	pregnancy	has	an	adverse	effect	on	
child	neurocognitive	outcome,	it	appears	to	mainly	relate	to	the	pre‐school	period.	
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1  | BACKGROUND
The	thalidomide	tragedy	involved	an	apparently	benign	drug	being	
taken	for	a	condition	that	is	common	in	early	pregnancy	(nausea	and	
vomiting);	its	teratogenic	effect	was	discovered	because	many	of	the	
offspring	were	born	with	striking	and	unusual	malformations.1 Ever 
since,	there	has	been	a	concern	that	relatively	common	adverse	ef‐
fects	would	not	be	easily	identified,	especially	if	they	were	not	ap‐
parent	immediately	after	the	child	was	born.	Few	such	effects	have	
been	discovered,	but	few	drugs	taken	in	pregnancy	have	been	inves‐
tigated	for	outcomes	that	would	take	many	years	to	be	recognised.	
This	 is	 particularly	 (but	 not	 exclusively)	 true	 of	 over‐the‐counter	
medications,	currently	the	most	common	of	which	is	paracetamol.
In	general,	despite	evidence	that	paracetamol	crosses	the	pla‐
centa2	and	 is	a	known	endocrine	disruptor3	and	a	COX	 inhibitor,4 
the	medical	 profession	 is	 relatively	 relaxed	 about	 the	 use	 of	 this	
analgesic	 in	 pregnancy;	 it	 is	 usually	 claimed	 to	 be	 the	 analgesic	
of	 choice.	 It	 is	 true	 that	 it	 has	 not	 been	 implicated	 in	major	mal‐
formations,5	 but	 there	has	been	 consistent	 evidence	 that	women	
who	take	paracetamol	in	pregnancy	increase	the	risk	of	their	child	
developing	asthma.6	 In	addition,	there	 is	now	increasing	evidence	
that	prenatal	exposure	to	the	drug	increases	the	risk	of	childhood	
hyperactivity	 and	diagnosed	ADHD.7,8	There	 is	 some	evidence	of	
an	increased	risk	of	autism9	but	one	study	found	that	this	was	con‐
ditional	on	the	autistic	child	being	hyperactive.10	In	addition,	other	
neurocognitive	outcomes	have	been	suggested	and	these	include:	
various	behaviour	problems;11	poorer	attention	and	executive	func‐
tion;12	diagnoses	of	Oppositional	Defiant	Disorder	(ODD)13 and ce‐
rebral	palsy.14	In	contrast,	there	are	no	reported	associations	in	the	
offspring	of	psychotic	symptoms15	or	miscarriage,16	and	contradic‐
tory	findings	with	IQ.17,18
Because	 it	 is	 so	 common,	 and	no	 links	with	 congenital	malfor‐
mations	have	been	made,	paracetamol	 is	 considered	 the	analgesic	
of	 choice	 for	 pregnant	women.19	 It	 is	 commonly	 taken	 in	 Europe,	
with	estimates	of	 fetal	exposure	 from	over	40%	of	pregnancies	 in	
Spain,9	 55%	 in	Denmark7	 to	 65%	 in	 France.20	When	 assessing	 ef‐
fects	 of	 prenatal	 exposures	 to	 the	 child	with	 a	 neurocognitive	 or	
behavioural	problem,	maternal	 recall	 of	events	 in	 a	pregnancy	oc‐
curring	years	earlier,	is	likely	to	result	in	failure	to	record	many	com‐
mon	exposures,	particularly	if	she	has	had	more	than	one	pregnancy.	
Consequently,	the	most	efficient	and	effective	method	is	to	use	data	
collected	 longitudinally,	 starting	 in	pregnancy.	This	we	do	here	by	
analysing	 information	collected	by	 the	Avon	Longitudinal	Study	of	
Parents	 and	 Children	 (ALSPAC).	 First,	 we	 determined	 the	 factors	
that	were	independently	associated	with	the	intake	of	paracetamol	
using	an	exposome	technique,21	and	then	taking	these	factors	into	
account,	 we	 determined	 independent	 associations	 with	 cognitive	
and	behavioural	outcomes	of	the	offspring.
2  | METHODS
Pregnant	 women	 who	 were	 resident	 in	 Avon,	 UK	 with	 expected	
dates	of	delivery	between	1st	April	1991	and	31st	December	1992	
were	invited	to	take	part	in	the	Avon	Longitudinal	Study	of	Parents	
and	Children	 (ALSPAC).22‐24	The	 initial	 number	of	pregnancies	en‐
rolled	was	 14	 541	 (for	 these	 at	 least	 one	 questionnaire	 had	 been	
returned).	Of	 these	 initial	 pregnancies,	 14	 150	 reached	 32	weeks	
(391	 having	 miscarried,	 been	 terminated	 or	 delivered	 before	 this	
gestation).	Questionnaires	sent	out	at	this	stage	 included	 informa‐
tion	on	paracetamol	intake,	and	were	returned	by	12	418	(88%)	of	
It	 is	 important	 that	 these	 results	be	 tested	using	other	datasets	or	methodologies	
before	assuming	that	they	are	causal.
K E Y W O R D S
ALSPAC,	child	cognitive	outcomes,	childhood	behaviour,	exposome,	paracetamol,	prenatal	
medication
Synopsis
Study Question
Does	paracetamol	consumption	at	18‐32	weeks	of	gesta‐
tion	affect	childhood	neurocognition	or	behaviour?
What's already known
Previous	 epidemiological	 studies	 concerning	 possible	
adverse	 effects	 of	 paracetamol	 (acetaminophen)	 con‐
sumption	 in	pregnancy	have	 suggested	associations	with	
cognition,	and	childhood	behaviour,	particularly	 involving	
hyperactivity	and/or	attention	problems.
What this study adds
Using	a	large	prospective	cohort	of	14,062	children,	linked	
to	information	on	child	cognitive	and	behavioural	outcomes	
from	6	months	to	17	years,	we	have	shown	that	paraceta‐
mol	consumption	between	18	and	32	weeks	gestation	was	
associated	with	adverse	trends	in	pre‐school	child	behav‐
iour,	 but	 the	 associations	were	no	 longer	 present	 by	 the	
end	of	primary	school	(age	10‐11	years).	Boys	appeared	to	
be	more	susceptible	than	girls	to	possible	behavioural	ef‐
fects	of	the	drug.
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these	women.	The	study	website	contains	details	of	all	the	data	that	
are	available	through	a	fully	searchable	data	dictionary	and	variable	
search	tool:	http://www.brist	ol.ac.uk/alspa	c/resea	rcher	s/our‐data/.	
Ethical	approval	for	the	study	was	obtained	from	the	ALSPAC	Ethics	
and	 Law	 Committee	 and	 the	 Local	 Research	 Ethics	 Committees	
(ALEC;	IRB00003312)	(registered	on	the	Office	of	Human	Research	
Protections	database	as	U	Bristol	IRB	#1).	Informed	consent	for	the	
use	 of	 data	 collected	 via	 questionnaires	 and	 clinics	 was	 obtained	
from	 participants	 following	 the	 recommendations	 of	 the	 ALSPAC	
Ethics	and	Law	Committee	at	the	time.25	Further	detail	can	be	found	
on	the	study	website:	http://www.brist	ol.ac.uk/alspa	c/resea	rcher	s/
resea	rch‐ethic	s/
2.1 | Exposure
Women	 in	 the	 study	 were	 sent	 a	 questionnaire	 entitled	 ‘Your	
Pregnancy’	at	about	32	weeks	gestation.	Of	the	14	150	women	in	
the	study,	12	418	(88%)	returned	the	questionnaire,	and	12	025	of	
these	 replied	 to	 the	 question	 on	 paracetamol	 use.	Data	were	 not	
available	for	women	who	had	delivered	prior	to	32	weeks	gestation,	
and	 those	 few	who	did	not	enrol	 in	 the	study	until	after	 the	baby	
was	born.
The	questions	asked	were:	‘Please indicate how often you have taken 
the following pills in the last three months’. (a) Aspirin; (b) Paracetamol; 
(c) Codeine; (d) Mogadon or other sleeping tablets; (e) Valium or other 
tranquilliser.	Possible	responses	were	as	follows:	everyday; most days; 
sometimes; not at all.	 The	 proportion	 answering	 positively	 to	 each	
question	(ie	any	use)	were	as	follows:	3.3%;	43.9%;	2.0%;	0.7%	and	
0.2%,	respectively.	We	only	consider	the	paracetamol	responses	in	
this	paper.	It	should	be	noted	that	only	0.9%	of	the	study	mothers	
reported	taking	paracetamol	on	most	days,	and	only	0.2%	every	day;	
the	remainder	answered	‘sometimes’.
2.2 | Outcomes
2.2.1 | Choice of outcomes
ALSPAC	has	collected	a	unique	quantity	of	information	on	the	study	
offspring,	 including	 biological	markers,	 physiological	 and	 psychiat‐
ric	tests	as	well	as	details	of	many	neurocognitive	measures.	In	this	
paper,	we	have	chosen	to	study	two	of	the	domains	most	mentioned	
in	 the	 literature	 and	 summarised	 in	 the	 introduction:	measures	 of	
cognition	and	behaviour.	We	have	tested	the	hypotheses	that	par‐
acetamol	taken	in	the	period	between	18	and	32	weeks	of	pregnancy	
Measure Age No. of tests
No. of tests (%) 
at P < .001
Cognitive	tests
IQ36 8	y 6 5	(83)
15	y 6 6	(100)
Memory37 8	y 2 0
10 y 2 0
17 y 2 0
Temperament
Carey	temperament26,27 6	mo 10 5	(50)
24	mo 10 5	(50)
EAS	temperament30 38	mo 4 1	(25)
Behaviour
Rutter31 42	mo 5 4	(80)
SDQ28	–	mother 47	mo 6 4	(67)
6	y 6 4	(67)
9 y 6 4	(67)
11 y 6 4	(67)
SDQ28	–	teacher 7‐8	y 6 1	(17)
10‐11 y 6 0
Feeding	difficulties 7 y 1 0
DAWBA29	outcomes
‐	Anxieties 7 y 10 2	(20)
‐	Compulsions 7 y 5 0
‐	Troublesome	behaviour 7 y 2 2	(100)
‐	Activity	&	attention 7 y 9 9	(100)
Selective	attention	tests38 8	y,	11	y 25 0
TA B L E  1  Assessment	of	cognitive	
and	behavioural	outcomes	considered	
and	the	no.	(proportion)	with	unadjusted	
associations	of	P	<	.0001	with	
paracetamol	taken	between	18	and	32	wk	
of	pregnancy
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increases	the	risk	of	behaviour	problems,	particularly	hyperactivity	
and	 conduct	 disorder,	 and	 we	 aim	 to	 determine	 the	 associations	
with	cognition,	having	no	prior	hypotheses.	We	have	excluded	from	
consideration	 at	 this	 point	 associations	 with	 educational	 abilities,	
speech	 characteristics,	 motor	 development	 and	 psychiatric	 meas‐
ures	of	depression	or	psychosis—they	will	be	considered	 in	subse‐
quent	publications.
In	order	to	determine	which	outcome	measures	to	analyse,	we	
first	determined	which	of	135	outcomes	measured	on	a	continuous	
scale	were	associated	with	paracetamol	on	unadjusted	analyses	at	
P	<	0.0001	 (Table	1).	To	do	this,	we	determined	the	proportion	of	
each	type	(ie	cognition,	temperament	and	behaviour)	and	age	when	
the	 measure	 was	 obtained.	 Firstly,	 we	 considered	 cognitive	 tests	
involving	 IQ	 and	memory.	Of	18	measures,	 11	 (61%)	were	 associ‐
ated—each	involving	different	measures	of	IQ.	Consideration	of	the	
24	measures	of	temperament	identified	associations	with	11	(46%)	
measures,	 the	majority	being	of	 the	Carey	temperament	at	ages	6	
and	 24	months.26,27	 There	were	 93	measures	 of	 behaviour—asso‐
ciations	were	particularly	noted	with	measures	from	the	Strengths	
and	Difficulties	Questionnaire	 (SDQ)28	where	20	of	29	behaviours	
reported	by	the	mother	were	associated	but	only	1	of	12	reported	
by	the	teacher;	also	associated	were	measures	of	troublesome	be‐
haviour	 and	 of	 activity	 and	 attention	 as	 reported	 in	 the	 DAWBA	
set	of	questions29	administered	at	7	years.	 In	contrast,	 the	admin‐
istration	of	 the	TEACh	 tasks	of	 selective	attention	 showed	no	as‐
sociations,	in	contradiction	to	the	findings	of	the	Danish	study	of	a	
subsample	of	5‐year	olds.12
From	 these	 unadjusted	 analyses,	 we	 chose	 the	 following	 do‐
mains	 for	 detailed	 analysis:	 cognition—the	 IQ	 test	 results	 at	 ages	
8	and	15	 (n	=	11);	 temperament—ten	Carey	and	one	Emotionality,	
Activity,	and	Sociability	(EAS)30	temperament	variables	(n	=	11);	be‐
haviour—the	Rutter,31	SDQ	and	DAWBA	activity	and	attention	vari‐
ables	 (n	=	34).	Descriptions	of	the	 items	are	 in	the	Supplementary	
Information.
2.3 | Statistical analysis
The	analyses	were	undertaken	in	two	strands:	(a)	a	determination	of	
those	variables	to	be	included	as	potential	confounders,	and	(b)	an	
assessment	of	the	relationship	between	paracetamol	and	outcome,	
taking	the	potential	confounders	into	account;	further	analyses	re‐
peated	the	analyses	for	boys	and	girls	separately.
1.	 The	 identification	 of	 potential	 confounders	 used	 an	 exposome	
technique	 as	 developed	 earlier.21	 This	 involves:	 (a)	 identifying	
all	 factors	 that	were	 associated	 at	P	 <	 .0001	with	 paracetamol	
intake	at	32	weeks	gestation	 in	unadjusted	analyses,	 (b)	putting	
them	 into	 meaningful	 groups	 based	 on	 physical	 or	 psycholog‐
ical	 attributes,	 (c)	 within	 each	 group	 using	 step‐wise	 logistic	
regression	 to	 select	 those	 variables	 independently	 associated	
with	 taking	 the	 drug,	 (d)	 combining	 the	 variables	 identified	 as	
independent	 from	 each	 group	 with	 those	 from	 other	 groups,	
then	 use	 a	 step‐wise	 logistic	 regression	 to	 identify	 variables	
to	 include	 in	 a	 final	 model.	 The	 variables	 in	 this	 model	 will	
be	 those	 used	 as	 potential	 confounders.
2.	 Altogether	 135	 unadjusted	 relationships	 between	 paracetamol	
intake	18‐32	weeks	and	 the	 cognitive	 and	behaviour	outcomes	
recorded	by	ALSPAC	were	considered.	Of	these,	41%	(n	=	56)	as‐
sociated	at	P	<	.001	were	identified	for	adjusted	analysis	(Table	1).	
In	instances,	where	more	than	one	similar	outcome	were	available	
a	decision	was	made	to	use	the	outcome	with	the	highest	num‐
bers	of	children	involved.
In	general,	the	outcomes	were	measured	on	a	continuous	scale	and	thus	
multivariable	linear	regression	was	employed	using	the	raw	scores.	Since	
there	were	no	differences	between	boys	and	girls	in	regard	to	the	like‐
lihood	that	they	had	been	exposed	to	paracetamol	(50.5%	and	49.5%,	
respectively),	sex	of	the	child	was	not	used	as	a	confounder.	However,	
in	order	 to	determine	whether	associations	differed	by	sex,	 stratified	
analyses	were	undertaken	to	determine	whether	there	were	apparent	
interactions—if	so,	interaction	terms	would	be	included	in	the	analyses.
2.3.1 | Missing data
We	have	 not	modelled	 using	missing	 data	 techniques	 as	 the	 data	
are	 unlikely	 to	 be	 missing	 at	 random.	 The	 proportion	 of	 missing	
data	 varies	 for	 each	 variable,	 but	 can	 be	 readily	 ascertained	 from	
the	ALSPAC	study	data	dictionary	(www.brist	ol.ac.uk/alspa	c/resea	
rcher	s/our‐data);	it	varies	from	0%	for	the	sex	of	the	child	to	62%	for	
the	IQ	measure	at	age	15.
3  | RESULTS
3.1 | Identification of potential confounders
As	noted	earlier,	43.9%	of	the	women	answering	the	questionnaire	
administered	 at	 32	 weeks	 gestation	 reported	 taking	 paracetamol	
since	18	weeks.	In	order	to	identify	potential	confounders,	we	con‐
sidered	all	features	of	the	mother	that	were	relevant	to	the	period	
18‐32	weeks	pregnancy	or	earlier	in	pregnancy	or	during	the	moth‐
er's	previous	life.	Of	the	factors	considered,	33	were	associated	at	
P	<	.0001	with	paracetamol	intake,	and	a	further	two	variables	were	
considered	as	likely	associations	even	though	not	associated	at	this	
level	 (mother	had	 rheumatism	and	 social	 class	of	partner).	 The	35	
variables	were	divided	into	four	groups	(Table	S1):
a.	 background	 aspects	 of	 health	 (history	 of	 the	 following	 condi‐
tions:	 hay	 fever,	 asthma,	 indigestion,	 eczema,	 back	 pain,	 pelvic	
inflammatory	disease,	hypertension,	migraine,	severe	depression	
and	 rheumatism).
b.	 current	health	 in	the	period	18‐32	weeks	 (in	poor	health,	had	a	
cold,	had	‘flu,	had	an	infection,	had	a	headache,	had	backache,	high	
scores	 on	 anxiety,	malaise	 and	 depression	 scales	 at	 32	weeks).	
Since	there	was	no	obvious	category	for	body	mass	index	(BMI;	
weight	 (Kg)/height	 (m)2)	 pre‐pregnancy,	 it	 was	 included	 in	 this	
group.
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c.	 maternal	lifestyle	(‘healthy’	dietary	pattern	score	and	‘processed’	
dietary	pattern	score,32	whether	ever	smoked	regularly,	number	
of	cigarettes	smoked	per	day	at	32	weeks,	any	passive	smoking,	
alcohol	 consumed	 (none	 v	 any),	 amount	 of	 caffeine	 consumed	
from	beverages).
d.	 social	conditions	(living	in	public	housing,	crowding	in	home	(per‐
sons/room),	maternal	education	level,	domestic	chemical	cleaning	
score,33	whether	mother	worked	in	pregnancy,	age	at	first	preg‐
nancy,	parity	(no.	of	previous	births)	and	social	class	(based	on	the	
current	occupation	of	the	mother's	partner).
Intra‐group	analyses	resulted	in	nine	variables	being	eliminated	from	
the	following	groups:	(a)	hay	fever,	eczema	and	rheumatism;	(b)	back‐
ache	and	malaise;	(c)	ever	smoked	and	passive	smoking;	(d)	maternal	
education	and	social	class.	The	15	surviving	variables	from	(a)	and	(b)	
were	offered	together,	with	the	result	that	pelvic	inflammatory	dis‐
ease,	hypertension	and	a	history	of	severe	depression	were	dropped.	
In	parallel,	the	11	surviving	variables	from	(c)	and	(d)	were	offered	to‐
gether—caffeine	consumption,	residing	in	public	housing	and	crowd‐
ing	index	were	dropped.	The	20	surviving	variables	were	then	offered	
together,	and	five	variables	were	eliminated	(anxiety	and	depression	
at	 32	 weeks;	 no.	 of	 cigarettes	 smoked	 at	 32	 weeks;	 whether	 the	
mother	worked	during	pregnancy,	and	her	age	at	first	pregnancy).
The	15	independent	predictors	of	taking	paracetamol	between	
18	and	32	weeks	are	shown	in	Table	2.	Not	unexpectedly,	the	fac‐
tor	with	the	largest	odds	ratio	was	the	report	of	headache(s)	in	the	
18‐32	week	period.	This	was	independent	of	having	a	history	of	mi‐
graine.	Protective	factors	were	close	adherence	to	eating	a	‘healthy’	
dietary	 pattern	 and	 of	 taking	 no	 alcohol	 during	 this	 time	 period.	
Interestingly,	 none	 of	 the	 traditional	 measures	 of	 socio‐economic	
status	were	retained	in	the	model.
The	 15	 variables	 were	 treated	 as	 possible	 confounders,	 since	
we	did	not	consider	it	warranted	to	carry	out	similar	modelling	pro‐
cedures	 for	 each	 of	 the	 56	 outcomes	 and	 thence	 identify	 factors	
predictive	of	both	paracetamol	intake	and	each	outcome.	The	con‐
founders	 identified	 in	 this	way	would	necessarily	 include	 some	of	
the	factors	predictive	of	paracetamol	intake.
3.2 | Availability of potential confounders
The	15	 variables	 comprising	 the	 final	 potential	 confounder	model	
were	 obtained	 from	 four	 different	 questionnaires	 administered	
Feature Took drug Did not take drug OR (95% CI) P
Medical	history
History	of	asthma 13.6% 9.9% 1.32	(1.15,	1.52) 1.0 × 10−4
History	of	
indigestion
75.7% 66.2% 1.19	(1.08,	1.32) 0.001
History	of	back	pain 52.6% 42.7% 1.11	(1.01,	1.22) 0.028
History	of	migraine 53.7% 36.5% 1.46	(1.33,	1.60) 5.4	×	10−16
Pre‐pregnancy	BMIa M	23.3 M	22.6 1.03	(1.02,	1.04) 8.0	×	10−6
In	period	18‐32	wk
In	poor	healthb 32.8% 18.8% 1.18	(1.12,	1.25) 8.0	×	10−9
Had	a	cold 48.5% 34.3% 1.44	(1.32,	1.59) 7.7 × 10−15
Had	‘flu 8.7% 3.8% 1.37	(1.10,	1.70) 0.005
Had	other	infection 7.1% 3.4% 1.33	(1.19,	1.49) 8.2	×	10−7
Had	a	headache 80.6% 46.4% 3.89	(3.52,	4.29) 5.5	×	10−160
Lifestyle
Healthy	diet	scorea M	‐	0.11 M	+	0.09 0.87	(0.83,	0.92) 2.4	×	10−8
Processed	diet	
scorea
M	+	0.07 M	‐	0.05 1.06	(1.01,	1.11) 0.014
Drank	no	alcohol 45.0% 53.7% 0.66	(0.60,	0.72) 1.1 × 10−19
Social	conditions
Domestic	chemical	
scorea
M	11.4 M	10.5 1.02	(1.01,	1.03) 0.002
Parity	1+ 62.6% 49.4% 1.18	(1.12,	1.24) 6.2	×	10−11
Features	of	the	mother	that	independently	predicted	whether	she	had	taken	paracetamol	in	the	
period	18‐32	weeks.	Final	model	–	N	=	9522;	pseudo‐R2	=	14.35%.	Details	of	variables	are	given	in	
the	Supplementary	Material.
BMI,	body	mass	index;	CI,	confidence	interval;	M,	mean;	OR,	odds	ratio	or	mean	difference.
aOdds	ratio	for	a	continuous	scale.	
bSubjective	measure	reported	by	the	mother	at	32	wk.	
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during	pregnancy.	Not	every	woman	completed	all	questionnaires	or	
questions,	consequently	data	concerning	all	15	factors	were	avail‐
able	for	only	9522	(79%)	of	the	12	025	mothers	who	completed	the	
paracetamol	question	in	the	32‐week	questionnaire.	The	differences	
concerning	those	who	were	perforce	excluded	from	later	analyses	
are	shown	by	outcome	measure	in	Table	S2.	In	general,	confining	the	
analyses	by	paracetamol	to	the	cases	where	all	potential	confounder	
information	 is	 available	 results	 in	 the	 loss	of	15%‐17%	of	 children	
concerning	the	scales	answered	by	the	parent	or	resulting	from	test‐
ing	in	the	ALSPAC	clinic	(eg	IQ	at	8)	and	20%	of	the	teacher	reports.
3.3 | Adjusted analyses for cognition variables
Of	the	18	measures	of	cognitive	function	considered,	the	eleven	re‐
lating	to	IQ	were	considered	further;	almost	all	subtests	and	overall	
measures	showed	strong	inverse	unadjusted	associations	(Table	S3).	
However,	on	allowing	for	the	15	potential	confounders,	although	all	
measures	continued	to	show	inverse	associations,	the	effects	were	
largely	attenuated:	only	one	showed	a	significant	trend—the	‘Freedom	
from	distractibility’	subset	of	IQ	measured	at	age	8	(mean	difference	
(MD)	−0.35	(95%	CI	−0.70,	−0.00))	(Table	3).	Stratification	by	sex	of	
the	child	showed	no	differences	of	note	(Tables	4,	5	and	S3a,b).
3.4 | Adjusted analyses for temperament variables
There	were	11	measures	of	the	child's	temperament	showing	a	sig‐
nificant	 unadjusted	 association	with	maternal	 paracetamol	 intake.	
On	adjustment,	 two	trends	retained	significance:	adaptability	 (MD	
0.33	(95%	CI	0.05,	0.60))	at	6	months	and	persistence	(MD	0.36	(95%	
CI	0.12,	0.60))	at	24	months	(Tables	3	and	S4).	Stratification	by	sex	
showed	that	for	boys,	there	were	five	temperaments	that	were	not	
attenuated:	 approach	 (MD	 0.44	 (95%	 CI	 0.03,	 0.86)),	 adaptability	
(MD	0.44	(95%	CI	0.06,	0.82),	distractibility	(MD	0.40	(95%	CI	0.02,	
0.78))	and	measure	of	a	difficult	baby	(MD	1.35	(95%	CI	0.15,	2.54))	
all	at	6	months,	and	persistence	at	24	months	(MD	0.36	(95%	CI	0.03,	
0.69));	for	girls	only	persistence	at	24	months	was	retained	(MD	0.36	
(95%	CI	0.02,	0.70))	(Tables	4,	5	and	S4a,b).	None	of	the	interactions	
between	the	sexes	were	statistically	significant.
3.5 | Adjusted analyses for hyperactive behaviour
Measures	 of	 attention	 and	 excessive	 activity	 used	 the	 Strengths	
and	Difficulties	Questionnaire	 (SDQ)	measures28	 at	 various	 ages	
from	3	to	11	years	including	both	maternal	and	teacher	reports,	as	
well	as	from	the	adapted	Development	and	Well‐being	Assessment	
(DAWBA)	series	of	questions	answered	by	mother	and	teacher	at	
age	7‐8.29	Of	the	seven	measures	of	hyperactivity	using	the	SDQ	
type	questions,	only	two	survived	adjustment—hyperactivity	iden‐
tified	in	her	child	by	the	mother	at	ages	42	and	47	months	(Table	3).	
There	were	no	teacher	associations,	although	the	measure	in	school	
year	 3	was	 of	 borderline‐adjusted	 association	 (MD	 0.16	 (95%	CI	
−0.01,	+0.33)).	When	the	boys	and	girls	were	considered	separately	
(Table	 S5a,b),	 there	were	 similar	 significant	 adjusted	 associations	
for	 hyperactivity	 at	 ages	 42	 and	 47	 months,	 and	 for	 girls,	 the	
teacher	report	at	seven	was	also	significant	(Tables	4	and	5).
The	 DAWBA	 scales	 separated	 hyperactive	 and	 attentive	 be‐
haviour.	Of	the	13	measures	investigated	for	all	children,	all	of	the	
measures	of	 activity	were	attenuated,	but	 the	attention	measures	
were	more	likely	to	have	survived	adjustment,	at	least	at	the	<0.10	
level.	 The	 most	 relevant	 adjusted	 score	 was	 for	 attention	 as	 as‐
sessed	by	the	teacher	in	school	year	3	(MD	0.45	(95%	CI	0.11,	0.79)).	
There	were	no	such	associations	for	the	teachers'	report	for	pupils	
in	school	year	6	(ages	10‐11)	(Table	S6).	When	boys	were	considered	
separately,	all	the	associations	were	attenuated,	but	among	the	girls,	
TA B L E  3  Mean	differences	in	outcome	measures	associated	
(P	<	.05)	with	paracetamol	exposure	at	18‐32	wk	gestation
Measure Na
AMD  
(95% CI) Ptrend
Cognition
IQ:	Freedom	from	dis‐
tractibility	at	8	y
5448 −0.35	
(−0.69,	−0.00)
0.048
Temperament
M.Adaptability	at	6	mo 8166 +0.33	
(+0.05,	+0.60)
0.019
M.Persistence	at	24	mo 8074 +0.36	
(+0.12,	+0.60)
0.003
Behaviour
M.SDQ	Hyperactivity	at	
42	mo
7849 +0.16	
(+0.07,	+0.25)
3.3	×	10−4
M.SDQ	Hyperactivity	at	
47	mo
7508 +0.22	
(+0.10,	+0.33)
1.8	×	10−4
T.DAWBA	Attention	at	
7‐8	y
4378 +0.45	
(+0.11,	+0.79)
0.009
T.DAWBA	Attention/
Activity	at	7‐8	y
4376 +0.53	
(+0.02,	+1.04)
0.042
M.SDQ	Conduct	prob‐
lems	at	42	mo
7849 +0.22	
(+0.10,	+0.33)
1.9 × 10−4
M.SDQ	Conduct	prob‐
lems	at	47	mo
7508 +0.08	
(+0.01,	+0.15)
0.023
M.SDQ	Conduct	prob‐
lems	at	81	mo
6742 +0.10	
(+0.02,	+0.18)
0.010
M.SDQ	Total	behavioural	
difficultiesb	at	42	mo
7849 +0.54	
(+0.26,	+0.82)
1.3	×	10−4
M.SDQ	Total	behavioural	
difficultiesb	at	47	mo
7508 +0.31	
(+0.08,	+0.53)
0.007
For	definitions	of	DAWBA	and	SDQ	see	Supplementary	Material;	the	
IQ	tests	were	performed	by	ALSPAC	psychologists;	the	behaviour	
measures	were	reported	by	mothers	(labelled	‘M’)	within	self‐comple‐
tion	questionnaires,	with	the	exception	of	those	labelled	‘T’	which	were	
completed	by	teachers.	Details	of	outcome	measures	are	given	in	the	
Supplementary	Material.
AMD,	adjusted	mean	difference	of	score.
aAdjusting	for	all	factors	in	Table	2.	
bCombination	of	hyperactivity,	conduct,	emotional	and	peer	problems.	
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there	were	adjusted	associations	with	both	the	attention	score	(MD	
0.66	(95%	CI	0.27,	1.04))	and	a	combination	of	the	attention	and	ac‐
tivity	scales	(MD	0.79	(95%	CI	0.27,	1.32)).
3.6 | Conduct/troublesome behaviour
A	scale	for	 identification	of	conduct	problems	was	 included	 in	the	
SDQ	 and	 in	 two	 scales	 included	 in	 the	 DAWBA	 as	 asked	 of	 the	
mother	and	the	teacher.	There	were	adjusted	associations	evident	
for	the	children	aged	42,	47	and	81	months	(Table	3).	When	the	two	
sexes	were	analysed	separately,	 it	can	be	seen	that	for	girls	all	the	
associations	were	 attenuated	 (Table	 4)	 but,	 for	 boys,	 associations	
were	apparent	with	the	SDQ	scale	at	ages	42,	47,	81	and	115	months	
(Table	5).	There	were	no	significant	differences	between	the	associa‐
tions	for	the	two	sexes	(Tables	4,	5	and	S7a,b).
3.7 | Emotional behaviour
As	with	 the	other	 scales	based	on	 the	SDQ	or	Rutter,	 seven	ages	
were	assessed—five	by	mothers	and	 two	by	 teachers.	All	were	at‐
tenuated	on	adjustment	(Tables	S8a,b).
3.8 | Total behavioural difficulties
Summation	 of	 the	 hyperactivity,	 conduct,	 peer	 and	 emotional	 dif‐
ficulty	 scales	 of	 the	 SDQ	was	 used	 to	 create	 a	 score	 of	 total	 be‐
havioural	difficulties.	Although	all	seven	measures	were	associated	
with	 maternal	 paracetamol	 intake	 in	 pregnancy,	 the	 associations	
were	 attenuated	 for	 all	 except	 the	 two	 early	 measures	 (Table	 3).	
Stratification	 by	 sex	 showed	 associations	 on	 adjustment	with	 the	
three	earliest	measures	for	boys,	and	the	42‐month	measure	for	girls	
(Tables	4	and	5	and	S9a,b).	 In	all	 these	 instances,	 the	child	whose	
mother	had	taken	paracetamol	had	more	behavioural	problems.
4  | COMMENT
4.1 | Principal findings
In	this	paper,	we	have	investigated	135	continuous	outcomes	related	
to	cognition,	temperament	and	behaviour	in	children	born	to	women	
who	had	taken	paracetamol	at	some	stage	between	18	and	32	weeks	
of	pregnancy	compared	with	those	who	had	not.	In	all,	56	(41%)	were	
associated	 at	 the	 0.1%	 level	 before	 adjustment.	 In	 order	 to	 deter‐
mine	appropriate	confounders,	we	used	a	hypothesis‐free	exposome	
technique	to	identify	15	features	of	the	mothers	that	independently	
predicted	whether	she	had	taken	paracetamol.	We	then	used	multi‐
ple	regression	to	assess	the	level	of	association	between	paraceta‐
mol	 intake	 and	 each	 of	 the	 56	 outcomes	 after	 adjustment	 for	 the	
15	potential	confounders;	after	adjustment	12	of	 the	56	remained	
significantly	associated.	The	12	variables	were	almost	entirely	 fea‐
tures	of	hyperactive	or	attentive	behaviour—being	less	adaptable	at	
6	months,	having	poorer	persistence	at	24	months,	having	elevated	
scores	on	the	hyperactive	behaviour	scales	at	42	and	47	months	(ma‐
ternal	reports)	and	teacher	reports	of	poor	attention	in	school	year	
3	(age	7‐8	years).	Hands‐on	testing	to	determine	IQ	at	age	8	identi‐
fied	a	subcategory	‘freedom	from	distractibility’	that	has	an	associa‐
tion	with	attention.34	The	other	factors	associating	with	paracetamol	
were	conduct	problems	at	ages	42	and	47	months,	and	total	behav‐
iour	difficulties	(which	include	hyperactivity)	at	these	ages.
This	 is	 not	 the	 first	 time	 that	 fetal	 paracetamol	 exposure	 has	
been	 linked	 to	 hyperactivity,	 but	 it	 is	 probably	 the	 first	 time	 that	
the	potential	confounders	have	been	identified	using	an	exposome	
technique;	 this	 technique	 was	 hypothesis‐free,	 and	 thus	 likely	 to	
TA B L E  4  Among	daughters,	mean	differences	in	outcome	
measures	associated	with	paracetamol	exposure	at	18‐32	wk	
gestation
Measure Na
AMD  
(95% CI) Ptrend
Cognition
IQ:	Freedom	from	distract‐
ibility	at	8	y
2726 −0.41	
(−0.88,	+0.06)
0.084
Temperament
M.Adaptability	at	6	mo 3933 +0.215	
(−0.19,	+0.62)
0.293
M.Persistence	at	24	mo 3883 +0.36	
(+0.02,	+0.70)
0.039
Behaviour
M.SDQ	Hyperactivity	at	
42	mo
3781 +0.17	
(+0.05,	+0.30)
0.006
M.SDQ	Hyperactivity	at	
47	mo
3613 +0.25	
(+0.09,	+0.41)
0.002
T.SDQ	Hyperactivity	at	
7‐8	y
2177 +0.21	
(+0.02,	+0.40)
0.033
T.DAWBA	Attention	at	
7‐8	y
2181 +0.66	
(+0.27,	+1.04)
0.001
T.DAWBA	Attention/
Activity	at	7‐8	y
2484 −0.11	
(−0.41,	+0.19)
0.478
M.SDQ	Conduct	problems	
at	42	mo
3781 +0.16	
(−0.00,	+0.32)
0.050
M.SDQ	Conduct	problems	
at	47	mo
3613 +0.06	
(−0.04,	+0.16)
0.273
M.SDQ	Conduct	problems	
at	81	mo
3266 +0.08	
(−0.03,	+0.19)
0.169
M.SDQ	Total	behavioural	
difficultiesb	at	42	mo
3781 +0.49	
(+0.11,	+0.88)
0.012
M.SDQ	Total	behavioural	
difficultiesb	at	47	mo
3613 +0.26	
(−0.05,	+0.57)
0.100
Outcome	measures	were	either	included	in	Table	3,	or	have	shown	
effects	at	P	<	.05.	Details	of	outcome	measures	are	given	in	the	
Supplementary	Material.
For	definitions	of	DAWBA	and	SDQ	see	Supplementary	Material;	the	
IQ	tests	were	performed	by	ALSPAC	psychologists;	the	behaviour	
measures	were	reported	by	mothers	(labelled	‘M’)	within	self‐comple‐
tion	questionnaires,	with	the	exception	of	those	labelled	‘T’	which	were	
completed	by	teachers.
aAdjusting	for	all	factors	in	Table	2.	
bCombination	of	hyperactivity,	conduct,	emotional	and	peer	problems.	
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identify	some	factors	that	had	not	previously	been	considered	to	be	
confounders.	One	other	study	has	used	the	ALSPAC	data	to	inves‐
tigate	 associations	 between	maternal	 paracetamol	 intake	 in	 preg‐
nancy	(both	pre‐18	weeks	and	between	18	and	32	weeks)	in	regard	
to	hyperactivity	and	other	behaviour	measures	 (using	the	SDQ)	at	
81	months.	They	showed	significant	associations,	particularly	with	
taking	 the	 drug	 in	 the	 period	 18‐32	weeks	 and	 children	with	 the	
worst	 levels	 of	 hyperactivity,	 conduct	 disorder,	 emotionality	 and	
total	behaviour	difficulties.	Their	strategy	included	taking	a	number	
of	 confounders	 into	 account,	 but	 also	 assessing	whether	 paternal	
consumption	of	paracetamol,	or	intake	by	the	mother	5	years	later	
showed	 similar	 associations.11	 Our	 analysis	 also	 using	 these	 out‐
comes	at	81	months	showed	that	there	was	an	association	with	con‐
duct	disorder,	 none	with	 emotional	 symptoms	and	 associations	of	
borderline	significance	only	with	hyperactivity	and	total	behavioural	
difficulties	after	allowing	for	the	15	potential	confounders	(Tables	3	
and	S4‐S9).	These	differences	could	have	been	because	of	the	differ‐
ent	choices	of	factors	adjusted	for,	or	a	genuine	difference	between	
the	dichotomy	of	identifying	the	worst	10%	on	the	different	scales.
Results	from	other	longitudinal	studies	concerning	neurocogni‐
tive	outcomes	have	been	reviewed	by	Bauer	and	colleagues	in	2018.35 
They	identified	nine	studies	from	five	cohorts,	the	Norwegian	MoBA	
and	the	Danish	DNBC	being	the	largest	and	most	informative.	There	
were	no	two	studies	that	measured	the	exposure,	the	confounders	
or	the	outcomes	 in	the	same	way.	Nevertheless,	the	conclusion	of	
the	 review	was	 that	 ‘associations	were	strongest	 for	hyperactivity	
and	attention‐related	outcomes’.	This	supports	our	findings.
In	 order	 to	 determine	 the	 possible	 associations	 of	 an	 environ‐
mental	exposure	with	an	outcome	X,	a	major	task	is	to	ensure	that	
the	analyses	have	appropriately	adjusted	for	factors	that	are	associ‐
ated	with	the	exposure.	Here,	we	have	used	an	exposome	technique	
to	model	 all	 available	 ALSPAC	 data	 concerning	 the	 study	mother	
prior	to	32	weeks	gestation	to	identify	the	environmental	features	
that	need	to	be	taken	into	account	when	analysing	consequences	of	
the	mother's	 consumption	of	paracetamol	between	weeks	18	and	
32	of	gestation.
The	following	steps	were	undertaken:	(a)	unadjusted	assessment	
of	 all	 environmental	 features	 that	 concerned	 the	woman	 prior	 to	
and	during	pregnancy	up	until	the	date	on	which	paracetamol	was	
collected	at	32	weeks;	(b)	selection	from	(a)	of	33	associations	with	
P	<	 .0001,	and	added	inclusion	of	two	variables	thought	to	be	 im‐
portant—rheumatism	 and	 social	 class;	 (c)	Division	 of	 these	 factors	
TA B L E  5  Among	sons,	mean	differences	in	outcome	measures	associated	with	paracetamol	exposure	at	18‐32	wk	gestation
Measure Na AMD (95% CI) Ptrend
Cognition
IQ:	Freedom	from	distractibility	at	8y 2722 −0.27	(−0.79,	+0.24) 0.249
Temperament
M.Adaptability	at	6m 4233 +0.44	(+0.06,	+0.82) 0.037
M.Approach	at	6m 4231 +0.44	(+0.03,	+0.86) 0.037
M.Distractibility	at	6m 4234 +0.40	(+0.02,	+0.78) 0.040
M.Difficult	baby	at	6m 4537 +1.35	(+0.15,	+2.54) 0.027
M.Persistence	at	24	m 4191 +0.36	(+0.03,	+0.69) 0.032
Behaviour
M.SDQ	Hyperactivity	at	42m 4068 +0.17	(+0.04,	+0.29) 0.010
M.SDQ	Hyperactivity	at	47m 3895 +0.19	(+0.03,	+0.36) 0.019
T.DAWBA	Attention	at	7‐8	y 2197 +0.29	(−0.24,	+0.81) 0.286
T.DAWBA	Attention/Activity	at	7‐8	y 2195 +0.34	(−0.49,	+1.16) 0.427
M.SDQ	Conduct	problems	at	42m 4068 +0.29	(+0.12,	+0.45) 0.001
M.SDQ	Conduct	problems	at	47m 3895 +0.10	(+0.00,	+0.20) 0.047
M.SDQ	Conduct	problems	at	81m 3476 +0.12	(+0.01,	+0.23) 0.027
M.SDQ	Conduct	problems	at	115m 3142 +0.12	(+0.01,	+0.24) 0.039
M.SDQ	Total	behavioural	difficultiesb	at	42m 4068 +0.61	(+0.21,	+1.00) 0.003
M.SDQ	Total	behavioural	difficultiesb	at	47m 3895 +0.35	(+0.03,	+0.67) 0.031
M.SDQ	Total	behavioural	difficultiesb	at	81m 3470 +0.37	(+0.01,	+0.73) 0.044
Outcome	measures	which	either	were	included	in	Table	3,	or	which	have	shown	adjusted	effects	at	P	<	.05.	Details	of	outcome	measures	are	given	in	
the	Supplementary	Material.
For	definitions	of	DAWBA	and	SDQ	see	Supplementary	Material;	the	IQ	tests	were	performed	by	ALSPAC	psychologists;	the	behaviour	measures	
were	reported	by	mothers	(labelled	‘M’)	within	self‐completion	questionnaires,	with	the	exception	of	those	labelled	‘T’	which	were	completed	by	
teachers.
aAdjusting	for	all	factors	in	Table	2.	
bCombination	of	hyperactivity,	conduct,	emotional	and	peer	problems.	
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into	 logical	 groups;	 (d)	 step‐wise	 logistic	 regression	 within	 each	
group;	 (e)	 combination	 of	 the	 results	 from	 the	 groups	 to	 create	 a	
final	 model	 containing	 15	 variables	 with	 a	 pseudo‐R2	 of	 14.35%.	
Interestingly,	the	modelling	exercise	(which	was	carried	out	using	a	
hypothesis‐free	approach)	rejected	many	of	the	features	that	were	
used	 as	 confounders	 by	 other	 studies	 such	 as	 use	 of	 other	medi‐
cations,	a	history	of	smoking,	maternal	age,	socio‐economic	status,	
maternal	education	level	and	psychiatric	illness.
We	repeated	the	analyses	separately	for	the	two	sexes	and	found	
that	the	associations	with	hyperactive	and	conduct	behaviour	were	
more	likely	to	be	found	among	the	boys	where	there	were	14	signifi‐
cant	adjusted	associations	(Table	5),	in	contrast	with	the	girls	with	only	
six	significant	adjusted	associations	(Table	4).	The	patterns	of	associa‐
tion	are	somewhat	different:	for	boys	(but	not	girls)	there	is	a	predom‐
inance	of	difficult	temperaments	at	6	months,	and	of	associations	with	
conduct	disorder	from	42	months	to	9	years,	and	of	total	behavioural	
difficulties	from	42	to	81	months.	In	contrast,	the	girls	are	more	likely	
than	the	boys	to	be	implicated	with	attention/hyperactive	behaviour	
especially	at	older	ages	(7‐8	years)	when	reported	by	the	teacher.
It	 is	 noteworthy	 that	 the	 literature	 review	 of	 Bauer	 and	 col‐
leagues35	 did	 not	 find	 results	 of	 neurocognitive	 associations	with	
prenatal	 paracetamol	 intake	 beyond	 the	 age	 of	 7.	 In	 the	 present	
study,	 we	 have	 shown	 that	 the	 strongest	 relationships	 with	 child	
behaviour	were	 identified	at	42	and	47	months,	and	that	the	SDQ	
associations	 diminished	 as	 the	 children	 became	 older—this	 being	
especially	true	of	the	boys.	We	showed	that,	although	others	have	
shown	an	association	with	 IQ	 in	the	DNBC,	this	was	at	age	5.	We	
found	only	a	marginal	association	with	one	subgroup	at	age	8,	and	
none	at	age	15.	This	raises	a	possibility	that	if	paracetamol	does	have	
an	adverse	effect	on	child	temperament	and	behaviour,	this	may	be	
confined	to	the	pre‐puberty	ages.
4.2 | Strengths of the study
A	strength	of	 this	study	 lies	 in	 the	fact	 that	 it	concerns	a	geographi‐
cally	defined	population	of	pregnant	women,	not	selected	in	any	way	
other	than	by	the	place	of	residence	(Avon)	and	the	expected	date	of	
delivery	(April	1991	to	December	1992).	Nevertheless,	although	about	
80%	of	the	eligible	population	took	part,	those	who	did	not	enrol	were	
more	likely	to	be	young,	to	smoke	and	be	from	the	more	deprived	social	
groups.	As	we	have	shown,	however,	these	factors	were	not	linked	to	the	
likelihood	of	the	woman	taking	paracetamol	in	the	period	18‐32	weeks	
gestation,	and	consequently	may	not	be	responsible	for	bias.
Another	advantage	 lies	 in	 the	 fact	 that	 the	 study	collected	 in‐
formation	from	a	variety	of	sources	including	hands‐on	assessments	
(eg	IQ	at	8;	the	TEACh	measures	of	attention),	structured	question‐
naires	completed	by	the	mother	(temperament	and	behaviour),	and	
the	teacher	(behaviour).	Thus,	if	there	were	particular	biases	with	the	
source	of	data	this	should	be	revealed;	in	fact,	most	of	the	positive	
findings	were	from	maternal	report,	and	the	independent	hands‐on	
test	 results	were	not	 related	 to	maternal	paracetamol	 intake.	This	
may,	however,	be	a	function	of	the	cognitive	test	rather	than	reveal‐
ing	a	defect	in	the	design.
4.3 | Limitations of the data
There	are	a	number	of	limitations.	(a)	Although	we	took	time	to	inves‐
tigate	possible	confounders	using	an	exposome	technique,	the	results	
are	necessarily	confined	 to	 the	 information	collected.	There	may	be	
many	other	features	that	should	have	been	adjusted	for	(residual	con‐
founding),	 and	 which	may	 change	 the	 conclusions	 of	 the	 paper.	 (b)	
Relevant	to	this	is	the	fact	that	we	used	a	very	statistically	stringent	
approach	 to	 identifying	 the	confounders	 from	the	data	collected	by	
ALSPAC—relaxing	the	P	values	used	for	selection	may	have	resulted	
in	a	wider	list	of	confounders.	(c)	It	is	important	to	emphasise	that	we	
examined	paracetamol	between	18	and	32	weeks	only	(but	not	in	early	
or	late	pregnancy).	(d)	We	captured	some	information	about	frequency	
of	paracetamol	use	but	the	numbers	of	frequent	users	were	too	small	
for	 further	 analyses.	 (e)	 Importantly,	 our	 analysis	 concentrated	 on	
using	the	continuous	data	collected	on	the	outcomes	considered;	this	
may	result	in	the	failure	to	recognise	strong	effects	in	the	tail(s)	of	the	
distribution.
4.4 | Interpretation
Unlike	most	of	 the	other	studies	 (see	 review	by	Bauer	et	al35),	we	
have	used	the	continuous	trait	scales	rather	than	a	dichotomy	iden‐
tifying	pathology.	This	gives	the	study	more	statistical	power	but,	on	
the	other	hand,	may	hide	important	associations.
4.5 | Conclusions
We	have	shown	that	paracetamol	taken	in	the	period	18‐32	weeks	
is	associated	with	aspects	of	child	attention	and	hyperactivity	until	
7	years	of	age,	but	there	is	little	sign	of	adverse	associations	at	later	
ages,	with	the	exception	of	their	sons	who	are	more	likely	to	demon‐
strate	conduct	problems	up	until	9	years	of	age.	Given	the	increase	
in	these	behaviours	it	will	be	important	to	assess	whether	they	are	
accompanied	by	difficulties	in	scholastic	achievements,	or	whether	
any	adverse	effects	survive	puberty.
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